A variety of lengths of hTERT promoter (− 205/+ 55, − 27/+ 55 [28], − 279/+ 5 [29], − 408/+ 5 [29], and − 408/+ 55) as well as the hTC hTERT/CMV enhancer fusion promoter [30] were cloned into an EGFP-expressing plasmid, then tested in Skov3 (p53 null) [22], Ovcar3 (p53 dominant negative, gain of function R248Q mutant) [22], and Kuramochi (p53 dominant negative D281Y aggregation mutant) [22] ovarian cancer cells as well as BJ normal human fibroblasts (p53 wild type) [27]. This evidence concerns the gene TP53 and ovarian cancer.